PetDx's flagship product, OncoK9, is a cfDNA-based multi-cancer early detection (MCED) blood test for dogs that leverages next-generation sequencing and proprietary bioinformatics. OncoK9 was clinically validated in the CANDiD study using samples prospectively collected from over 1,000 client-owned dogs across more than 40 clinical sites on four continents and demonstrated detection across about 30 canine cancer types. The test is recommended as an annual screening for higher-risk dogs and as an aid in diagnosis, and is currently available at many veterinary clinics across the U.S. PetDx plans to broaden adoption through its own commercial platform and strategic distribution partnerships, expand testing throughput at its central San Diego laboratory, and accelerate its R&D roadmap. The company highlights the large unmet need in veterinary cancer diagnostics and positions OncoK9 as a first-in-class liquid biopsy to bring genomic medicine advances from human oncology to pet health. PetDx has raised significant outside capital to support commercialization and R&D.

Total raised

$62M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2021